# A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)

> **NCT03740724** · PHASE1,PHASE2 · TERMINATED · sponsor: **Castle Creek Biosciences, LLC.** · enrollment: 1 (actual)

## Conditions studied

- Morphea
- Scleroderma, Localized
- Scleroderma

## Interventions

- **GENETIC:** FCX-013
- **DRUG:** veledimex

## Key facts

- **NCT ID:** NCT03740724
- **Lead sponsor:** Castle Creek Biosciences, LLC.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-12-18
- **Primary completion:** 2020-09-23
- **Final completion:** 2022-04-21
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2024-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03740724

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03740724, "A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03740724. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*